Mesoblast H2 2025 Earnings Report

Mesoblast EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.20
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Mesoblast Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $7.48 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Mesoblast Announcement Details

• Quarter: H2 2025
• Date: 8/27/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Mesoblast (NASDAQ:MESO) engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.